Literature DB >> 19383283

Europe combating cancer: the European Union's commitment to cancer research in the 6th Framework Programme.

Stefan Jungbluth1, Olaf Kelm, Jan-Willem van de Loo, Elengo Manoussaki, Maria Vidal, Manuel Hallen, Octavi Quintana Trias.   

Abstract

As one of the major health issues in Europe, cancer was a research priority in the 6th Framework Programme (2002-2006). About 485 million euros were devoted to this theme, which allowed funding of 108 multidisciplinary transnational projects. A significant part of them was large-scale initiatives addressing complex issues through a broad combination of competences. All major types of cancer were covered, as well as the three dimensions such as prevention, diagnostic and treatment, with a particular emphasis on translational research aiming at bringing basic knowledge on medical practice. This approach will be continued in the 7th Framework Programme (2007-2013), together with a strengthened effort to improve the coordination of European cancer research, which is fragmented and in which EU action represents only a small part. EU cancer research will also be addressed within the reinforced efforts in the areas of pharmaceutical and technological developments as well as common aetiological mechanisms of diseases that the 7th Framework Programme will undertake.

Entities:  

Mesh:

Year:  2007        PMID: 19383283      PMCID: PMC5543862          DOI: 10.1016/j.molonc.2007.01.002

Source DB:  PubMed          Journal:  Mol Oncol        ISSN: 1574-7891            Impact factor:   6.603


  5 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

2.  European Code Against Cancer and scientific justification: third version (2003).

Authors:  P Boyle; P Autier; H Bartelink; J Baselga; P Boffetta; J Burn; H J G Burns; L Christensen; L Denis; M Dicato; V Diehl; R Doll; S Franceschi; C R Gillis; N Gray; L Griciute; A Hackshaw; M Kasler; M Kogevinas; S Kvinnsland; C La Vecchia; F Levi; J G McVie; P Maisonneuve; J M Martin-Moreno; J Newton Bishop; F Oleari; P Perrin; M Quinn; M Richards; U Ringborg; C Scully; E Siracka; H Storm; M Tubiana; T Tursz; U Veronesi; N Wald; W Weber; D G Zaridze; W Zatonski; H zur Hausen
Journal:  Ann Oncol       Date:  2003-07       Impact factor: 32.976

3.  NCI sets goal of eliminating suffering and death due to cancer by 2015.

Authors:  Andrew C von Eschenbach
Journal:  J Natl Med Assoc       Date:  2003-07       Impact factor: 1.798

4.  Europe combating cancer: the European Union's commitment to cancer research in the 6th Framework Programme.

Authors:  Stefan Jungbluth; Olaf Kelm; Jan-Willem van de Loo; Elengo Manoussaki; Maria Vidal; Manuel Hallen; Octavi Quintana Trias
Journal:  Mol Oncol       Date:  2007-03-14       Impact factor: 6.603

5.  Cancer incidence and mortality in Europe, 2004.

Authors:  P Boyle; J Ferlay
Journal:  Ann Oncol       Date:  2005-02-17       Impact factor: 32.976

  5 in total
  5 in total

1.  The role of funding and policies on innovation in cancer drug development.

Authors:  P Kanavos; R Sullivan; G Lewison; W Schurer; S Eckhouse; Z Vlachopioti
Journal:  Ecancermedicalscience       Date:  2010-02-03

2.  Europe combating cancer: the European Union's commitment to cancer research in the 6th Framework Programme.

Authors:  Stefan Jungbluth; Olaf Kelm; Jan-Willem van de Loo; Elengo Manoussaki; Maria Vidal; Manuel Hallen; Octavi Quintana Trias
Journal:  Mol Oncol       Date:  2007-03-14       Impact factor: 6.603

3.  Emphasising the European Union's Commitment to Cancer Research: a helicopter view of the Seventh Framework Programme for Research and Technological Development.

Authors:  Jan-Willem van de Loo; Dominika Trzaska; Karim Berkouk; Maria Vidal; Ruxandra Draghia-Akli
Journal:  Oncologist       Date:  2012

Review 4.  The future of trials in surgical oncology.

Authors:  Peter Naredi; Michael P La Quaglia
Journal:  Nat Rev Clin Oncol       Date:  2015-04-14       Impact factor: 66.675

5.  Trends in the global funding and activity of cancer research.

Authors:  Seth Eckhouse; Grant Lewison; Richard Sullivan
Journal:  Mol Oncol       Date:  2008-03-27       Impact factor: 6.603

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.